Pharmaceuticals, Biotechnology and Life Sciences
Transgene, a company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases, announced the launch and terms of a share capital increase with shareholders’ preferential subscription rights for a total gross amount of circa €48 million, issue premium included (the “Rights Issue”).
Genomic Vision, DNA molecular combing specialist that develops tests for the diagnostics market and tools for the life sciences research market, has presented, at the Annual Meeting of the American Society of Human Genetics, the initial results of the pilot study undertaken with Quest Diagnostics that aims to identify a biomarker to improve genetic counseling for Spinal Muscular Atrophy (SMA) in the African-American population.
The company on Thursday said the Placing Shares are being offered by an accelerated bookbuild. Zeus Capital and N+1 Singer will be acting as joint bookrunners in connection with the Bookbuild, Quantum Pharma has said.
FDA approves Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for people with a specific type of metastatic lung cancer.
GW Pharmaceuticals plc has announced leaving AIM and canceling trading in London, to continue trading only on NASDAQ.
Advanced Oncotherapy , the developer of proton therapy systems for cancer treatment, has announced on Tuesday that planning permission for the Harley Street site was granted.
KEOPSYS Group holding company, acquired for € 5 million, 93.8% of the capital of EURODYNE, which holds 1,184,513 QUANTEL shares and 1,928,579 voting rights, representing 14.6% of the capital and 21.3% of the voting rights of QUANTEL.
Quantum Pharma names new CEO and makes other board changes
@qp_group
Allergan announced that Sweden has received the Marketing Authorisation for BELKYRA (deoxycholic acid) after being granted approval by the Swedish Medical Products Agency (MPA).
Ablynx has extended for a second time its research collaboration with a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, known as MSD outside the United States and Canada, to develop and commercialise Nanobody candidates directed towards an undisclosed voltage gated ion channel.